These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 2024682

  • 1. Angiotensin-I converting enzyme inhibition: clinical effects in chronic renal disease.
    de Jong PE, Heeg JE, Apperloo AJ, de Zeeuw D.
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):85-8. PubMed ID: 2024682
    [No Abstract] [Full Text] [Related]

  • 2. [The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases].
    Kutyrina IM, Tareeva IE, Gerasimenko OI, Rogov VA, Miroshnichenko NG.
    Ter Arkh; 1995 May; 67(5):20-3. PubMed ID: 7638769
    [Abstract] [Full Text] [Related]

  • 3. Converting enzyme inhibitors: structural and hemodynamic effects on failing kidney.
    Stella A, Buccianti G.
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):81-4. PubMed ID: 2024681
    [No Abstract] [Full Text] [Related]

  • 4. [Further evidence for the renoprotective effect of ACE inhibitors: ramipril protects against the progression of chronic renal insufficiency in non-diabetic nephropathy with nephrotic proteinuria].
    Mayr M, Dickenmann MJ.
    Schweiz Med Wochenschr; 2000 Apr 01; 130(13):491. PubMed ID: 10812646
    [No Abstract] [Full Text] [Related]

  • 5. Angiotensin converting enzyme inhibition in non-diabetic nephropathy with non-nephrotic proteinuria.
    Pennesi M, Torre G.
    Pediatr Nephrol; 2000 May 01; 14(5):438. PubMed ID: 10805476
    [No Abstract] [Full Text] [Related]

  • 6. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?
    Ryan MJ, Tuttle KR.
    Curr Opin Nephrol Hypertens; 2008 Sep 01; 17(5):443-9. PubMed ID: 18695383
    [Abstract] [Full Text] [Related]

  • 7. How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?
    Zhang X, Hou FF.
    Chin Med J (Engl); 2007 Feb 05; 120(3):243-5. PubMed ID: 17355830
    [No Abstract] [Full Text] [Related]

  • 8. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr 05; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 9. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.
    Lubrano R, Soscia F, Elli M, Ventriglia F, Raggi C, Travasso E, Scateni S, Di Maio V, Versacci P, Masciangelo R, Romero S.
    Pediatrics; 2006 Sep 05; 118(3):e833-8. PubMed ID: 16923922
    [Abstract] [Full Text] [Related]

  • 10. Effects on angiotensin-converting enzyme inhibition on renal hemodynamics in renal artery stenosis.
    Levenson DJ, Dzau VJ.
    Kidney Int Suppl; 1987 May 05; 20():S173-9. PubMed ID: 3037167
    [No Abstract] [Full Text] [Related]

  • 11. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Boner G.
    Isr J Med Sci; 1996 Dec 05; 32(12):1217-21. PubMed ID: 9007157
    [Abstract] [Full Text] [Related]

  • 12. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS, Weinberg AJ, Zappe DH.
    J Renin Angiotensin Aldosterone Syst; 2000 Sep 05; 1(3):217-33. PubMed ID: 11881029
    [No Abstract] [Full Text] [Related]

  • 13. Ace inhibition in renal disease: risks and benefits.
    Campanacci L, Fabris B, Fischetti F, Bardelli M, Vran F, Carretta R.
    Clin Exp Hypertens; 1993 Sep 05; 15 Suppl 1():173-86. PubMed ID: 8513308
    [Abstract] [Full Text] [Related]

  • 14. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct 05; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-converting enzyme inhibitor for slowing progression of diabetic and nondiabetic kidney disease.
    Myers BD, Boothroyd D, Olshen RA.
    J Am Soc Nephrol; 1998 Dec 05; 9(12 Suppl):S66-70. PubMed ID: 11443771
    [Abstract] [Full Text] [Related]

  • 16. [Renal function during treatment with angiotensin converting enzyme inhibitors].
    Rasmussen K, Heitmann M, Nielsen JI, Møgelvang JC.
    Ugeskr Laeger; 1995 Sep 25; 157(39):5377-81. PubMed ID: 7483049
    [Abstract] [Full Text] [Related]

  • 17. [ACE inhibitors--a potential new group of drugs for treatment of kidney diseases].
    Podracká L, Sasinka M, Böör A.
    Cesk Pediatr; 1993 Jan 25; 48(1):29-31. PubMed ID: 8477465
    [Abstract] [Full Text] [Related]

  • 18. [The significance of angiotensin-converting enzyme inhibitors genotype for ACEi response in patients with chronic allograft nephropathy].
    Savin M, Petronić V.
    Srp Arh Celok Lek; 2005 Jan 25; 133(3-4):194-8. PubMed ID: 16206711
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease.
    Adarkwah CC, Gandjour A.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Apr 25; 11(2):215-23. PubMed ID: 21476823
    [Abstract] [Full Text] [Related]

  • 20. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure.
    Barnas U, Schmidt A, Haas M, Oberbauer R, Mayer G.
    Nephrol Dial Transplant; 1996 Sep 25; 11(9):1822-4. PubMed ID: 8918629
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.